Establishing Wholly-owned Subsidiary to Enable BBK Worldwide to Better Serve Asia-Pacific Clinical Trial Enrollment Concerns
NEWTON, Mass., March 18 /PRNewswire/ -- BBK Worldwide, a global leader in patient recruitment for clinical trials, has announced the opening of BBK Worldwide -- Osaka, G.K., in Osaka, Japan. The company will be committed to supporting Japanese pharmaceutical, biotechnology, and medical device companies, as well as CROs and SMOs, to help these groups more rapidly and effectively enroll and retain patients as participants in clinical research studies.
Throughout the world, the single most costly delay in bringing new treatments to market is the slow enrollment of clinical trials, with each day a trial doesn't enroll potentially equivalent to millions of dollars in lost revenue due to treatment patent limitations. Moreover, it takes an average of 2.5 years longer for a drug to become available in Japan than in the U.S. or Europe, according to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
Understanding the primary causes for this specific delay was the first step for BBK in exploring the Japanese marketplace, according to company co-founder and president Bonnie Brescia. "We conducted in-depth interviews with medical directors and leaders of clinical trial teams at many of the major Japanese pharmaceutical companies," said Brescia, "And we found that four of the five top reasons for delay were issues that we have solved for our clients' studies in more than 30 countries throughout the world. Inefficient patient accrual, contracting with sites, attitudes of patients or referring physicians, and insufficient or inaccurate enrollment feasibility planning -- when we heard these concerns, we knew that we could offer real value to the Japanese marketplace."
"While we believe we can offer expert consultation and services immediately for study sponsors with recruitmen
|SOURCE BBK Worldwide|
Copyright©2009 PR Newswire.
All rights reserved